Revenue Recognition

6 Months Ended

Jun. 30, 2025

Revenue from Contract with Customer [Abstract]

Revenue Recognition

16. Revenue Recognition

The following table provides information about disaggregated revenue by product and services:

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Product sales, net	$	2,379	$	9,963	$	11,397	$	22,806
Processing and storage fees, net		1,275		1,278		2,683		2,565
License, royalty and other		2,082		870		3,082		1,421
Net revenues	$	5,736	$	12,111	$	17,162	$	26,792

Net revenues include: (i) sales of biomaterial products, including Biovance, Biovance 3L, Rebound^TM, Interfyl, and CentaFlex, of which our direct sales are included in Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.

The following table provides changes in deferred revenue from contract liabilities:

	2025
Balance at January 1	$	6,255
Deferral of revenue*		2,939
Recognition of unearned revenue		(2,822	)
Balance at June 30	$	6,372

* Deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.

(1)	Deferral of revenue includes $1,208 in 2025 resulting from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.
(2)	Recognition of unearned revenue includes $1,195 that was included in the beginning deferred revenue balance at January 1, 2025.